<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00837915</url>
  </required_header>
  <id_info>
    <org_study_id>AA01111</org_study_id>
    <nct_id>NCT00837915</nct_id>
  </id_info>
  <brief_title>Bioequivalnce Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fasting Conditions</brief_title>
  <official_title>Comparative, Randomized, Single-Dose, Fully Replicated, 4-Way Crossover Bioavailability Study of Ranbaxy and Schering (Claritin_D® 24 Hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets, in Healthy Adult Volunteers Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ranbaxy Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ranbaxy Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to compare the single-dose relative bioavailability of
      Ranbaxy and Schering (Claritin-D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg
      Extended-Release Tablets, in a fully replicated design, under fasting conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was conducted as an open-label, randomized, Single-Dose, Fully replicated, 4-way
      Crossover Study to compare the single-dose relative bioavailability of Ranbaxy and Schering
      (Claritin_D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release
      Tablets, in Healthy adult Volunteers Under Fasting Conditions A total of 40 subjects (30
      males and 10 females) were included in this study, of which 36 (27 males and 9 females)
      finished the study according to the protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">November 2002</completion_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative bioavailability between Ranbaxy and Schering (Claritin-D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets under fasting conditions</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets of Ranbaxy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(Claritin-D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male or female volunteers, 18-45 years of age

          -  Weighing at least 60 kg for males and 52 kg for females and within 15% of their ideal
             weights (Table of &quot;Desirable Weights of Adults&quot;, Metropolitan Life Insurance Company,
             1983);

          -  Medically healthy subjects with clinically normal laboratory profiles;

          -  Females of childbearing potential should either be sexually inactive (abstinent) for
             14 days prior to the study and throughout the study or be using one of the following
             acceptable birth control methods:

               -  surgically sterile (bilateral tubal ligation, hysterectomy bilateral
                  oophorectomy) 6 months minimum

               -  IUD in place for at least 3 months

               -  barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to
                  the start of the study and .throughout the study

               -  surgical sterilization of the partner (vasectomy for 6 months minimum

               -  hormonal contraceptives for at least 3 months prior to the start of the study

          -  Other birth control methods may be deemed acceptable.

          -  Postmenopausal women with amenorrhea for at least 2 years will be eligible;

          -  Voluntarily consent to participate in the study.

        Exclusion Criteria:

          -  Subject candidates must not be enrolled in the study if they meet any of the following
             criteria:

          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             hematologic,gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or
             psychiatric disease.

          -  In addition, history or presence of:

               -  alcoholism or drug abuse within the past year

               -  hypersensitivity or idiosyncratic reaction to loratidine or any other H1-receptor
                  antagonist

               -  hypersensitivity or idiosyncratic reaction to pseudoephederine or any other
                  sympatomimetic amines

               -  glaucoma or hypermetropia

          -  Subjects receiving a monoamine oxidase (MAO) inhibitor or within 14 days of stopping
             use of an MAO inhibitor, or any sympathomimetic amines.

          -  Subjects who have used any drugs or other substances known to be strong inhibitors of
             CYP (cytochrome P450) enzymes within 10 days of study start.

          -  Subjects who have used any drugs or other substances known to be strong inducers of
             CYP (cytochrome P450) enzymes within 28 days of study start.

          -  Female subjects who are pregnant or lactating.

          -  Subjects who have been on an abnormal diet (for whatever reason) during the 28 days
             prior to the first dose.

          -  Subjects who, through completition of the study, would have donated in excess of:

               -  500 mL of blood in 14 days, or

               -  500-750 mL of blood in 14 days (unless approved by the principal Investigator),

               -  1000 mL of blood in 90 days,

               -  1250 mL of blood in 120 days,

               -  1500 mL of blood in 180 days,

               -  2000 mL of blood in 270 days,

               -  2500 mL of blood in 1 days,

          -  Subjects who have participated in another clinical trial within 28 days prior to the
             study start.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MDS Pharma Services</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4R2N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.ranbaxy.com</url>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/Enforce.html</url>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
  </link>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>February 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2009</study_first_posted>
  <last_update_submitted>February 5, 2009</last_update_submitted>
  <last_update_submitted_qc>February 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Tausif Monif</name_title>
    <organization>Ranbaxy Research Labs</organization>
  </responsible_party>
  <keyword>Bioequivaelnce Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended Release Tablets</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

